|
gptkbp:instanceOf
|
antiviral drug
prodrug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2003
|
|
gptkbp:ATCCode
|
J05AE07
|
|
gptkbp:CASNumber
|
226700-79-4
|
|
gptkbp:chemicalFormula
|
C25H36N3O9PS
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to amprenavir
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:drugClass
|
protease inhibitor
|
|
gptkbp:eliminationHalfLife
|
7.7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasSMILES
|
CC(C)CN(C1=NC2=C(C=CC=C2)C(=N1)C3=CC=CC=C3)C(=O)OCCOP(=O)(OCCO)S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fosamprenavir
|
|
gptkbp:interactsWith
|
gptkb:efavirenz
gptkb:lopinavir
gptkb:ritonavir
gptkb:atazanavir
statins
indinavir
saquinavir
|
|
gptkbp:KEGGID
|
D04124
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Lexiva
gptkb:Telzir
|
|
gptkbp:mechanismOfAction
|
HIV-1 protease inhibition
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
585.62 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prodrugOf
|
gptkb:amprenavir
|
|
gptkbp:PubChem_CID
|
CHEMBL1201192
57718
64143
DB01319
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
|
|
gptkbp:synonym
|
gptkb:Lexiva
gptkb:Telzir
GW433908
|
|
gptkbp:UNII
|
6OQ3D3B4BG
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:bfsParent
|
gptkb:J05AE
|
|
gptkbp:bfsLayer
|
6
|